Feb 4 • 07:00 UTC 🇩🇰 Denmark Politiken

Sales of migraine medication drives Lundbeck's revenue growth

Danish pharmaceutical company Lundbeck has increased its revenue by 13% to 24.6 billion kroner in 2025, driven by the success of medications Vyepti and Rexulti, although net profit has not kept pace with sales growth.

📡 Similar Coverage